Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) Interview with Roger Tung, CEO discussing the company’s deuterium chemistry platform for creating new drugs which have superior properties—including enhanced clinical safety, tolerability […]
Management addition comes as FSD accelerates specialty cannabinoid pharmaceutical global expansion strategy TORONTO, Nov. 26, 2018 – FSD Pharma Inc. (“FSD Pharma” or “FSD”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today the appointment of […]
FSD Pharma (CSE: HUGE) (OTC: FSDDF) Investor Presentation by CEO Dr. Raza Bokhari at the New Green Frontier Cannabis Investor Conference
Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
SHANGHAI–Zoetis Inc. (NYSE: ZTS) today celebrated the start of construction on a combined global manufacturing and supply and research and development center in Suzhou, China, with a traditional groundbreaking ceremony. The new facility will focus […]